He X S, Raymon L P, Mattson M V, Eldefrawi M E, de Costa B R
Laboratory of Medicinal Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892.
J Med Chem. 1993 Apr 30;36(9):1188-93. doi: 10.1021/jm00061a009.
Piperidine and cyclohexyl ring homologues of the high-affinity dopamine (DA) uptake inhibitor 1-[1-(2-benzo[b]thienyl)cyclohexyl]piperidine (BTCP, 3) were each prepared in four steps from the appropriate cycloalkanones. These compounds were tested for their ability to displace [3H]BTCP and [3H]cocaine and to inhibit [3H]DA uptake in rat striatal homogenates. The ratios IC50([3H]cocaine)/IC50([3H]BTCP) ranged from 62 for BTCP to 1.5 for 1-[2-(benzo[b]thienyl)-cyclopentylamine (17); cocaine gave a ratio of 0.6. This indicates that BTCP is the most selective of all the compounds tested for sites labeled by [3H]BTCP whereas cocaine is most selective for sites labeled by [3H]cocaine. The wide differences in the relative abilities of these compounds to displace [3H]BTCP and [3H]cocaine suggests that these two radioligands are labeling different sites on the transporter. In general, the compounds structurally related to BTCP exhibited greater selectivity for sites labeled by [3H]BTCP. However, several of the BTCP-related derivatives showed greater (compared with BTCP and cocaine) ability to displace [3H]cocaine. Most notably, 1-[1-(2-benzo[b]thienyl)cyclohexyl]pyrrolidine (7) exhibited a 3.4-fold greater affinity for these sites compared with BTCP and a 9-fold greater affinity at these sites than cocaine. Most of the BTCP homologues displayed greater ability to inhibit [3H]DA uptake in rat forebrain synaptosomes than cocaine. BTCP and 7 were the most potent of all the compounds tested in terms of their ability to inhibit uptake of [3H]DA. IC50 ratios for [3H]cocaine binding/[3H]DA uptake ranged from 0.47 for 1-[1-(2-benzo[b]thienyl)cyclopentyl]homopiperidine (11) to 8.8 for 1-(2-benzo[b]thienyl)cyclohexylamine (4). The importance of this ratio remains unclear in terms of identification of potential cocaine antagonists. As for BTCP, all of the compounds tested showed Ki values > 10,000 nM for displacement of [3H]TCP from rat brain homogenates. These compounds were able to displace the highly selective sigma receptor probe [3H]-(+)-pentazocine from guinea pig brain homogenates with Ki values ranging from 125 to 9170 nM. The significance of their sigma-binding activity in light of their dopaminergic properties is unclear. The diverse binding properties of these compounds at the DA-uptake site and their spectrum of inhibitory activities for [3H]DA uptake identifies them as a useful base for the development of subtype selective probes at this site. These compounds will allow further study of the structure and function of the "cocaine" receptor as well as the development of potential cocaine antagonists.
高亲和力多巴胺(DA)摄取抑制剂1-[1-(2-苯并[b]噻吩基)环己基]哌啶(BTCP,3)的哌啶和环己基环同系物均由相应的环烷酮经四步反应制备而成。测试了这些化合物取代[3H]BTCP和[3H]可卡因以及抑制大鼠纹状体匀浆中[3H]DA摄取的能力。IC50([3H]可卡因)/IC50([3H]BTCP)的比值范围从BTCP的62到1-[2-(苯并[b]噻吩基)-环戊胺(17)的1.5;可卡因的该比值为0.6。这表明BTCP是所有测试化合物中对[3H]BTCP标记位点最具选择性的,而可卡因对[3H]可卡因标记位点最具选择性。这些化合物取代[3H]BTCP和[3H]可卡因的相对能力存在很大差异,这表明这两种放射性配体标记的是转运体上不同的位点。一般来说,与BTCP结构相关的化合物对[3H]BTCP标记的位点表现出更高的选择性。然而,一些与BTCP相关的衍生物显示出比BTCP和可卡因更强的取代[3H]可卡因的能力。最值得注意的是,1-[1-(2-苯并[b]噻吩基)环己基]吡咯烷(7)对这些位点的亲和力比BTCP高3.4倍,比可卡因高9倍。大多数BTCP同系物在抑制大鼠前脑突触体中[3H]DA摄取方面比可卡因表现出更强的能力。就抑制[3H]DA摄取的能力而言,BTCP和7是所有测试化合物中最有效的。[3H]可卡因结合/[